ASH 2025

I am a healthcare professional

Notice

Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.

Cookies

We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.

I am a healthcare professional in the United States

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

Agenda

Medical Materials

02:30 PM

Duration 15mins Room: OCCC - Tangerine Ballroom F1

Transcriptional profiling refines DLBCL classification and identifies subtypes with distinct therapeutic vulnerabilities

Godfrey J, Tumuluru S, Cooper A, Salles G, Trneny M, Lenz G, Morschhauser F, Jardin F, Harris W, Balasubramanian S, Sugidono M, Batlevi CL, Jiang Y, Kline J, Herrera A

Oncology | Diffuse large B cell lymphoma

02:45 PM

Duration 15mins Location: OCCC - Tangerine Ballroom F2

Fixed treatment duration subcutaneous mosunetuzumab▼ monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study

Sharman JP, Tun AM, Villasboas JC, Ayed A, Jani P, Biondo JML, Wu M, Hossain F, Mun Y, Chopra VS, Farighi R, Misleh J, Peles S, Flinn IW, Burke JM

Oncology | Diffuse large B cell lymphoma

03:45 PM

Duration 15mins Room: OCCC - Tangerine Ballroom F2

Mosunetuzumab▼ (Mosun) or glofitamab▼ (Glofit) in combination with golcadomide (Golca) demonstrates a manageable safety profile and encouraging efficacy in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)

Andreadis C, Avivi I, Goldschmidt N, Townsend W, Bastos-Oreiro M, Avigdor A, Riedell PA, Tzoran I, Eyre TA, McKay P, Abrisquesta P, Gonzales Barca E, Martin Garcia-Sancho A, Galimberti S, Kwan A, Relf J, Leung W, Mussai F, Ma CY, Petel A, Muller PY, Hou X, Fox CP

Oncology - Hematology | Non Hodgkin Lymphoma

08:15 PM

Duration 15mins Room: OCCC - West Hall D1

Tumor clearance, T-cell fitness and minimal residual disease (MRD) outcomes in patients with relapsed/refractory multiple myeloma (RRMM) treated with cevostamab plus pomalidomide and dexamethasone: Biomarker analyses from CAMMA 1 Arm B

Harrison S, Hasselbalch Riley C, Mian HS, Spencer A, Lavi N, Paris L, Mihalyova J, Popat R, Szarejko M, Grosicki S, Kim K, Sandhu I, Chebon S, Tyagi T, Sewpaul P, Richardson L, Trunzer K, Mishra A, Trudel S

Oncology | Multiple Myeloma

Duration 15mins Room: OCCC - Tangerine Ballroom F2

Fixed-duration subcutaneous (SC) mosunetuzumab▼, with maintenance therapy, in patients (pts) with previously untreated high-tumor burden follicular lymphoma (HTB FL): Longer follow-up and exploratory circulating tumor (ct)DNA analysis of the Phase II MorningSun study

Oncology | Follicular Lymphoma

09:00 PM

Duration 15mins Room: OCCC - W304ABCD

NXT007 prophylaxis in people with hemophilia A with or without FVIII inhibitors: a global phase I/II multiple-ascending-dose study

Mancuso ME, Matino D, Hart D, López-Jaime FJ, Schmitt C, Shapiro A, Ventriglia G, Kiialainen A, Young L, Catalani O, Belletrutti M, Chu T, Windyga J, Jiménez-Yuste V, Lehle M, Staber JM

Hematology | Hemophilia A

10:30 PM

Duration 120mins Orlando, USA

Economic and Clinical Impact of Emicizumab in People With Moderate and Severe Hemophilia A in the US

Lee JS, El Moustaid F, Lee L

Hematology | Hemophilia A

Duration 120mins Orlando, USA

Evolution of joint health and physical activity in people with hemophilia A without factor VIII inhibitors switching to emicizumab prophylaxis: A second interim analysis of the BEYOND ABR study

Kruse-Jarres R, Castaman G, Di Minno MND, Stephensen D, Lobet S, Barlera S, Brocchieri C, Jiménez-Yuste V

Hematology | Hemophilia A

Duration 120mins Orlando, USA

Promising response rates and manageable safety with mosunetuzumab▼ plus lenalidomide (Mosun-Len) in patients with relapsed/refractory (R/R) follicular lymphoma (FL): US extension cohort from the Phase III CELESTIMO study

Sano D, Bartlett N, Budde LE, Brinker B, Vaidya R, Babu S, Diefenbach C, Nze C, Ma CY, Knapp A, Doral MY, Chen V, Hauser P, Wei MC, Moorthy P, Phillips A, Surh N, Jan A, Purev E, Wagner-Johnston N

Oncology | Follicular Lymphoma

Duration 120mins Orlando, USA

Effects and interferences of NXT007, a novel bispecific antibody, on coagulation assays

Kiialainen A, Hart D, Schmitt C, Locke M

Hematology | Hemophilia A

Duration 120mins Orlando, USA

Fixed-duration subcutaneous mosunetuzumab▼ demonstrates sustained clinically meaningful outcomes in patients with previously untreated, low-tumor burden follicular lymphoma

Villasboas JC, Burke JM, Tun AM, Liu S, Sharman JP, Biondo JML, Jani P, Wu M, Mun Y, Chopra VS, Farighi R, Munoz J, Yunus F, Flinn IW, Budde LE

Oncology | Follicular Lymphoma

10:15 PM

Duration 15mins Room: OCCC - West Hall E1

Subcutaneous cevostamab demonstrates manageable safety and clinically meaningful activity in relapsed/refractory multiple myeloma (RRMM): First results from the Phase Ib CAMMA 3 study

Ho PJ, Quach H, Delimpasi S, Santoro A, Lee C H-S, Kint N, Faict S, Yu Y, Catalani O, Mishra A, Tyagi T, Devlin C, Sheikh S, Dimopoulos M

Oncology | Multiple Myeloma

11:00 PM

Duration 120mins Orlando, USA

Estimated total cost of care and patient out-of-pocket cost savings with first-line fixed duration venetoclax + obinutuzumab compared with treat-to-progression BTKi regimens among Medicare-eligible patients with chronic lymphocytic leukemia in the United States following the Inflation Reduction Act

Li SS, Rosettie KL, Manzoor BS, Reyes C El Moustaid F

Oncology | Chronic Lymphocytic Leukemia

Duration 120mins Orlando, USA

Real-World Treatment Patterns for Hemophilia A Since the Launch of Emicizumab in the US

Lee JS, Schuldt R, Lee L

Hematology | Hemophilia A

Duration 120mins Orlando, USA

RESHAPE: A non-interventional study of real-world treatment patterns and outcomes across age groups in people with severe hemophilia A in Latin America, Eastern Europe, Africa, Asia, and the Middle East

Lemos García F, Zortel M, Demyanov A, Ramos Mejia I, Tobaruela G, Gondos A, Petrov V, Khoubila N

Hematology | Hemophilia A

Duration 120mins Orlando, USA

Glofitamab▼ plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups

Abdulhaq H, Townsend W, Ku M, Gregory GP, Abramson JS, Huang HQ, Zhang H, Yoon DH, Kim WS, Ghesquieres H, Hertzberg M, Zhang QY, Kesavan M, Mulvihill E, Kallemeijn MJ, Ta R, Choeurng V, Lundberg L, Fox CP

Oncology | Diffuse large B cell lymphoma

Duration 120mins Orlando, USA

Fixed-duration intravenous mosunetuzumab▼ plus polatuzumab vedotin▼ combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study

Kamdar M, Chavez JC, Olszewski AJ, Assouline S, Lossos IS, Diefenbach C, Modi D, Sabry W, Naik S, Mehta A, Makadia S, Pham S, Penuel E, Wu H, Ead WS, To I, Houston DJ, Batlevi CL, Budde LE

Oncology | Non-Hodgkin Lymphoma

Duration 120mins Orlando, USA

A single-cell co-expression score of MYC and BCL2 identifies high-risk BCR-addicted DLBCL benefiting from polatuzumab vedotin▼ in the POLARIX trial

Sridhar S, Harris W, Tipgomut C, Pan-Hammarstrom Q, Salles G, Herrera A, Trněný M, Morschhauser F, Sugidono M, Batlevi CL, Jiang Y, Lenz G, Jeyasekharan A

Oncology - Hematology | Diffuse large B cell lymphoma

10:45 PM

Duration 15mins Room: OCCC - Tangerine Ballroom F1

Long-term follow-up with sustained progression-free survival (PFS) benefit after subcutaneous (SC) mosunetuzumab▼ in combination with polatuzumab vedotin▼ compared with rituximab plus polatuzumab vedotin▼ in patients with relapsed or refractory (R/R) B-cell non-Hodgkin Lymphoma

Ghosh N, Chavez JC, Bastos-Oreiro M, Diefenbach C, Lossos IS, Shah NN, Assouline S, Olszewski AJ, Naik S, Pham S, Wei MC, Batlevi CL, To I, Ead WS, Makadia S, Penuel E, Budde E

Oncology | Non-Hodgkin Lymphoma

Duration 120mins Room: OCCC - Sunburst Room (W340)

Preclinical evaluation of SPK-8011QQ, an adeno-associated virus gene therapy for people with hemophilia A leveraging the dirloctocogene samoparvovec platform encoding an activated protein C-resistant B-domain deleted factor VIII

Frey N, Receveur N, Enderlin-Paput M, Blanchard EL, Hanby H, Ramos J, David T

Hematology | Hemophilia A

11:00 PM

Duration 120mins Orlando, USA

Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) preferred fixed-duration treatments with less frequent administrations in the era of novel bispecific antibodies

Frosch Z, Masaquel A, Fox D, Reyes C, Cassoli L, Lai D, Myers K, Bussberg C, Patel K

Oncology | Diffuse large B cell lymphoma

Duration 120mins Orlando, USA

Exploratory analysis from HAVEN 1–4 to further contextualize injection-site reactions among people with hemophilia A receiving emicizumab

Bloomberg M, Eakle K, Niggli M, Dhalluin C, Lee L, Lim E, Carpenter SL

Hematology | Hemophilia A

Duration 120mins Orlando, USA

Use of emicizumab in patients with acquired hemophilia A: an interim safety analysis of a large-scale post-marketing surveillance study

Shima M, Fukutake K, Ogawa Y, Kamei Y, Sugita C, Yuri A, Kobayashi R, Ioka A, Matsushita T

Hematology | Hemophilia A

Duration 120mins Orlando, USA

Glofitamab▼ in combination with polatuzumab vedotin▼ demonstrates high and durable efficacy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) and third-line and later (3L+) setting: A subgroup analysis

Hutchings M, Sureda A, Bosch F, Stauffer Larsen T, Corradini P, Avigdor A, Terol MJ, Rueda Dominguez A, Pinto A, Skarbnik A, Cordoba R, Jørgensen J, Zinzani PL, Gurion R, Goldschmidt N, Leung W, Li D, Relf J, Kallemeijn MJ, Sellam G, Gritti G

Oncology | Non-Hodgkin Lymphoma

Duration 120mins Orlando, USA

Sustained clinical benefit of glofitamab▼ plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO

Abramson JS, Ku M, Fox CP, Huang HQ, Zhang H, Townsend W, Yoon DH, Kim WS, Abdulhaq H, Herbaux C, Zaucha JM, Chang H, Mulvihill E, Kesavan M, Kallemeijn M, Ta R, Choeurng V, Bottos A, Lundberg L, Gregory GP

Oncology | Diffuse large B cell lymphoma

Duration 120mins Orlando, USA

Fixed treatment duration mosunetuzumab▼ continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study

Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Kuruvilla J, Kim W, Cheah CY, Shadman M, Dietrich S, Ku M, El-Sharkawi D, Gutierrez N, Wei MC, Yin S, Sit J, Tracy S, Sabalvaro F, Penuel E, Bartlett NL

Oncology | Follicular Lymphoma

Duration 120mins Orlando, USA

Fixed-duration subcutaneous mosunetuzumab▼ continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study

Assouline S, Bartlett NL, Sehn LH, Giri P, Kuruvilla J, Schuster SJ, Yoon SS, Fay K, Hess G, Dreyling M, Gutierrez NC, Cybulski E, Sabalvaro F, Penuel E, Tracy S, Kuruvilla D, Chen J, Wiebking V, Wei MC, Budde LE

Oncology | Follicular Lymphoma

Duration 120mins Orlando, USA

Improvements in health-related quality of life (HRQoL) in the SUNMO study: subcutaneous (SC) mosunetuzumab▼ plus polatuzumab vedotin▼ (Mosun-Pola) versus rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after at least one prior therapy

Budde LE, Westin J, Zhang H, Maruyama D, Rego EM, Hong H, Goto H, Fesler M, Goodgame B, Li Z, Olszewski A, Ashby J, Yin S, Ead W, Janousek M, Pham S, Batlevi CL, Wei MC, Kim W

Oncology | Non-Hodgkin Lymphoma

Duration 120mins Orlando, USA

Pharmacodynamic biomarkers in people with hemophilia A receiving multiple ascending doses of NXT007

Kiialainen A, Schmitt C, Matino D, Staber JM, Mancuso ME, Jiménez-Yuste V, Windyga J, Shapiro A, Locke M, Hart D

Hematology | Hemophilia A

Duration 120mins Orlando, USA

Assessment of the prognostic value of FDG PET-derived markers and responses in POLARIX

Cottereau A-S, Herrera AF, Tilly H, Salles G, Chartier L, Sugidono M, Jemaa S, Carano RAD, Batlevi CL, Hapgood G, Lenz G, Morschhauser F

Oncology - Hematology | Diffuse large B cell lymphoma

Duration 120mins Orlando, USA

Outcomes of CAR T-cell therapies after prior treatment with fixed-duration mosunetuzumab▼ in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Braun A, Bartlett NL, Chihara D, Nastoupil LJ, Shadman M, Tzachanis D, Cochran H, Huang JJ, Wu M, Wei MC, Yin S, Hao JQ, Zhu Q, Mun Y, Budde LE

Oncology - Hematology | Non Hodgkin Lymphoma

Coming soon

I am a healthcare professional

Notice

Cookies

External site

ASH 2025